• BX795: Precision PDK1 Inhibition and Advanced In Vitro Evalu

  2026-06-10

  Explore how BX795, a potent PDK1 inhibitor, enables nuanced in vitro cancer drug response assessments. This article bridges kinase signaling insights with emerging viability metrics, advancing translational research.

• ABT-888 (Veliparib): Reliable PARP Inhibition for Cancer Res

  2026-06-10

  This article offers scenario-driven guidance for optimizing cell-based assays with ABT-888 (Veliparib), SKU A3002. Drawing on validated literature and product data, it addresses common laboratory challenges in DNA repair inhibition, assay reproducibility, and vendor selection. Researchers will gain practical insight into maximizing experimental reliability when investigating chemotherapy and radiation sensitization in colorectal and MSI tumor models.

• CRISPR Disruption of scaRNA1 Alters Spliceosomal RNA and Spl

  2026-06-09

  This study uses CRISPR-Cas9 gene editing to disrupt scaRNA1 in HEK293T cells, resulting in reduced pseudouridylation at a critical site on U2 snRNA and widespread changes in mRNA splicing. The findings provide mechanistic insight into the role of RNA-guided modifications in spliceosome function and transcriptome regulation.

• β-Elemene in Adipogenesis and Neuroprotection Workflows

  2026-06-09

  β-Elemene stands out as a versatile modulator of both adipogenesis and neuroprotection, enabling seamless cross-domain research in metabolic and neural models. This guide details actionable protocols, troubleshooting strategies, and advanced use-cases leveraging APExBIO's β-Elemene for enhanced reproducibility.

• Iptacopan Monotherapy Rapidly Normalizes Hemolysis in PNH

  2026-06-08

  This study demonstrates that Iptacopan (LNP023), a selective oral factor B inhibitor, achieves rapid normalization of hemolytic markers and reduces transfusion needs in patients with paroxysmal nocturnal hemoglobinuria (PNH). The findings support the therapeutic potential of targeting the alternative complement pathway upstream of C5, offering a new oral treatment approach for PNH management.

• Protein A/G Magnetic Beads: Redefining Precision in Complex

  2026-06-08

  Explore how Protein A/G Magnetic Beads enable precise antibody purification and advanced protein-protein interaction analysis across diverse biological systems. This article delves into their unique recombinant design, practical assay optimization, and new scientific frontiers.

• SM-102: Enabling Localized mRNA Delivery for Cancer Therapy

  2026-06-07

  Explore how SM-102, a key lipid nanoparticle component, revolutionizes localized mRNA delivery in cancer therapy. This article highlights unique clinical strategies and real-world protocol insights beyond typical vaccine development.

• Intravesical p21 mRNA-LNP Therapy for Bladder Cancer: Mechan

  2026-06-06

  This study pioneers a non-viral, intravesical delivery strategy using p21 mRNA–loaded lipid nanoparticles (LNPs) to restore tumor suppressor function in bladder cancer. By demonstrating robust tumor inhibition and mechanistic restoration of cell-cycle control, the work establishes a compelling case for localized mRNA therapeutics in urologic malignancies.

• CTCF’s Essential Role in Centromere Function and Mitotic Fid

  2026-06-05

  The reference study uncovers CTCF as a critical maintenance factor for centromere structure, chromosome alignment, and successful mitosis. By employing rapid CTCF depletion, the research delineates mechanistic distinctions between CTCF and CENP-E, offering new insights for cell division and cancer research.

• D-Lin-MC3-DMA: Redefining Ionizable Cationic Liposome Design

  2026-06-05

  Explore how D-Lin-MC3-DMA, a leading ionizable cationic liposome, is catalyzing next-generation siRNA and mRNA therapeutics with unprecedented efficiency. This article unveils distinct mechanistic insights and the impact of machine learning-guided LNP design on practical research workflows.

• Viral Regulation of RIPK3: Implications for Cell Death in In

  2026-06-04

  This study identifies a class of viral proteins (vIRD) in orthopoxviruses that induce proteasomal degradation of the necroptosis adaptor RIPK3, thereby modulating virus-induced inflammation and pathogenesis. These findings clarify how viruses manipulate necroptotic and apoptotic pathways, offering mechanistic insights relevant to both virology and programmed cell death research.

• LINC02870 Drives SNAIL Translation in Hepatocellular Carcino

  2026-06-04

  This study elucidates how the long non-coding RNA LINC02870 promotes hepatocellular carcinoma (HCC) progression by enhancing SNAIL translation through interaction with EIF4G1. The findings provide mechanistic insight into lncRNA-mediated translational control in HBV-related HCC, offering new avenues for biomarker discovery and therapeutic targeting.

• OTUD3 Stabilizes SLC7A11 to Drive Sunitinib Resistance in cc

  2026-06-03

  This study identifies OTUD3 as a critical regulator of sunitinib resistance in clear cell renal cell carcinoma (ccRCC) through stabilization of SLC7A11 and suppression of ferroptosis. These findings provide a mechanistic rationale for targeting OTUD3 to improve therapeutic outcomes in ccRCC.

• Cy3 Goat Anti-Rabbit IgG (H+L) Antibody: Workflow and QC Gui

  2026-06-03

  The Cy3 Goat Anti-Rabbit IgG (H+L) Antibody addresses the need for sensitive, specific detection of rabbit IgG in immunofluorescence, immunohistochemistry, and related assays. It is suitable for workflows requiring robust signal amplification but should not be used in diagnostic or clinical applications.

• DMG-PEG2000-NH2 in Next-Gen Amide Linkage for Lipid Nanocarr

  2026-06-02

  Explore the scientific underpinnings of DMG-PEG2000-NH2 as a NH2-PEG derivative for advanced lipid nanoparticle and liposomal drug delivery. This article uniquely focuses on the linker’s amide bond formation dynamics, protocol-critical parameters, and lessons from recent antimicrobial optimization breakthroughs.

8071 records 12/539 page Previous Next First page 上5页 1112131415 下5页 Last page